Cyclerion Therapeutics presented positive topline data today, July 28, 2022, during a webinar on their C6463-103 Phase 1 Schizophrenia study entitled, “A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia”!
CenExel-CNS CEO and Principal Investigator, David Walling, Ph.D., and CenExel-HRI Principal Investigator, Elan Cohen, Ph.D., conducted the study at their sites in Long Beach, CA and Marlton, NJ, respectively. The study can be found here: https://clinicaltrials.gov/ct2/show/NCT04972227
The data showed the drug, CY6463, was “well tolerated across all dose levels on top of antipsychotic regimen” and “shows strong cognition signal over placebo after only 2 weeks of dosing” in patients with stable schizophrenia. The study also included exploratory EEG assessments (resting state, qEEG, ERP, sleep EEG) – analysis of the data from these assessments is ongoing.
Congratulations to Cyclerion Therapeutics and Drs. Walling and Cohen on this exceptional study!
Check out the full press release: Cyclerion Therapeutics Announces Positive Topline Clinical (globenewswire.com)